Russia’s Sputnik V Vaccine Shows 92% Efficacy in Covid-19 Trial

Published : 12 Nov 2020

Around 10,000 medics and other high-risk participants from the red zones of Russian hospitals were administered Sputnik V last September. There are over 20,000 volunteers who were vaccinated with the first dose in the trials in 29 medical centers in Russia. The participants will be closely monitored for six months before a conclusion is to be reached.

The RDIF reported positive early results from the Phase I/II trials of Sputnik V, last September.

Sputnik, the first registered vaccine against COVID-19 ever created on a human adenoviral vector platform manifested 92% effectiveness as it entered the Phase III trial as reported by the Russian Direct Investment Fund (RDIF) and Gamaleya Center. 

The interim data is based on the double-blind, randomized, placebo-controlled trials and is being conducted on 40,000 participants in Russia. So far, Phase III trials are approved and are progressing in countries such as Belarus, the UAE, and Venezuela, as well as Phase II-III trials being conducted in India.

On the other hand, a study analyzing the vaccine’s safety and immunogenicity on elderly people is also progressing. Russian Federation Health Minister Mikhail Murashko said: “The use of the vaccine and the results of clinical trials demonstrate that it is an efficient solution to stop the spread of coronavirus infection,? preventive healthcare tool and this is the most successful path to defeat the pandemic.”

Russia is also set to initiate post-registration trials of a second Covid-19 vaccine developed by Siberia’s Vector institute on 15 November.

SOURCE: GlobalData.com